Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis

Courtney B Crayne; Timothy Beukelman

doi:10.1016/j.pcl.2018.03.005

Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis

Pediatr Clin North Am. 2018 Aug;65(4):657-674. doi: 10.1016/j.pcl.2018.03.005.

Authors

Courtney B Crayne¹, Timothy Beukelman²

Affiliations

¹ Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, 1600 7th Avenue South, CPPN G10, Birmingham, AL 35233, USA.
² Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, 1600 7th Avenue South, CPPN G10, Birmingham, AL 35233, USA. Electronic address: tbeukelman@peds.uab.edu.

PMID: 30031492
DOI: 10.1016/j.pcl.2018.03.005

Abstract

Juvenile idiopathic arthritis (JIA) comprises a group of heterogeneous diseases further divided into various categories based on shared clinical presentation, laboratory markers, and disease prognosis. Extra-articular complications include uveitis and growth abnormalities. Disease course and prognosis vary with respect to each JIA category and subsequently guide respective treatment. Over the past few decades, considerable treatment advances have significantly reduced the morbidity associated with childhood arthritis. Nevertheless, the treatments are not curative; many children continue to have active disease into adulthood. Emphasis is placed on the initiation of early aggressive therapy in hopes of delaying disease progression and inducing remission.

Keywords: Classification; Diagnosis; Juvenile idiopathic arthritis; Oligoarthritis; Polyarthritis; Treatment.

Publication types

Review

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Antirheumatic Agents / therapeutic use*
Arthritis, Juvenile* / classification
Arthritis, Juvenile* / diagnosis
Arthritis, Juvenile* / drug therapy
Child
Humans

Substances

Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents

Grants and funding

T32 AR069516/AR/NIAMS NIH HHS/United States